TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15915010

Group type: EXPERIMENTAL
Intervention: Formoterol pMDI (cumulative doses up to 96 microg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Formoterol DPI (cumulative doses up to 96 microg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Formoterol pMDI
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Formoterol DPI
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Formoterol pMDI and DPI
Number of subjects: 22
Study: 12409652

Group type: EXPERIMENTAL
Intervention: gemcitabine with or without a farnesyl transferase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: histone deacetylase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G17DT (antigastrin immunogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9‐nitrocamptothecin (topoisomerase I inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oxaliplatin to high‐dose 5FU plus leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid (fish oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ofloxacin plus ursodeoxycholic acid
Number of subjects: 0
Study: 10447843

Group type: EXPERIMENTAL
Intervention: Structured learning materials
Number of subjects: 228

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 228
Study: 7589056

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin at 200 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin at 800 mg
Number of subjects: 5
Study: 2237853

Group type: EXPERIMENTAL
Intervention: 100-150 mg acetylsalicylic acid per day for prophylaxis after acute myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg acetylsalicylic acid for cerebrovascular indications
Number of subjects: 0
Study: 109916

Group type: EXPERIMENTAL
Intervention: 20 mg disodium cromoglycate (DSCG) inhaled with a spinhaler 30 minutes before exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 mg of ketotifen taken orally 3 hours before exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo powder inhaled with a spinhaler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 16
Study: 31769533

Group type: EXPERIMENTAL
Intervention: Gluten (6-g gluten protein)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 36
Study: 29253167

Group type: EXPERIMENTAL
Intervention: Wearable cameras used to assess sun-protective behaviours and shade availability during school lunch-breaks.
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Wearable cameras for assessing specific sun-protective behaviours.
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Assessment of shade structures using wearable cameras.
Number of subjects: 168
Study: 28117400

Group type: EXPERIMENTAL
Intervention: Phytosterols-enriched low-fat milk (1.5 g phytosterols per day)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional low-fat milk
Number of subjects: 221
Study: 25449559

Group type: EXPERIMENTAL
Intervention: Robotic-assisted step training (RAST)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 23
Study: 23702253

Group type: EXPERIMENTAL
Intervention: Grape seed extract (GSE) 300 mg/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 70
Study: 21854344

Group type: EXPERIMENTAL
Intervention: Heavy resistance training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Explosive resistance training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Muscle endurance training
Number of subjects: 27
Study: 19473453

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 17953695

Group type: EXPERIMENTAL
Intervention: IL-6, TNF-A and LT-A gene polymorphisms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IL-6, TNF-A and LT-A gene polymorphisms in high responder (HR) subgroup
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IL-6, TNF-A and LT-A gene polymorphisms in low responder (LR) subgroup
Number of subjects: 96
Study: 15535409

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Nevirapine + Efavirenz (NVP+EFV)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Adverse events during follow-up
Number of subjects: 917
Study: 11206821

Group type: EXPERIMENTAL
Intervention: Sonographic measurement of fibulo‐trochlear angle in neutral position and under inversion stress
Number of subjects: 0
Study: 9272408

Group type: EXPERIMENTAL
Intervention: 1 mg oral ketotifen daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2 mg oral ketotifen daily
Number of subjects: 48
Study: 7871077

Group type: EXPERIMENTAL
Intervention: 1 mg sarmazenil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg sarmazenil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3544792

Group type: EXPERIMENTAL
Intervention: verapamil-SR, 240 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: regular formulation of verapamil, 120 mg 4 times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30300003

Group type: COMPARATOR
Intervention: Breath-held MRE
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Free-breathing MRE
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CS accelerated 2D GRE MRE
Number of subjects: 25
Study: 26462707

Group type: EXPERIMENTAL
Intervention: BMS 914392 (10 mg OD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BMS 914392 (10 mg TDS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BMS 914392 (20 mg TDS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24565698

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Revascularization alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nontreated segments
Number of subjects: 6
Study: 22394528

Group type: EXPERIMENTAL
Intervention: Fatigue management program
Number of subjects: 181
Study: 16202723

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg vaginally)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (vaginally)
Number of subjects: 34
Study: 12243291

Group type: EXPERIMENTAL
Intervention: Epidural morphine injection after combined spinal anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural morphine injection after epidural anaesthesia
Number of subjects: 30
Study: 10328327

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 14
Study: 7560628

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg, n = 22)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg three times a day, n = 19)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 59
Study: 1963183

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg twice daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg once daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem plus Atenolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination therapy (Diltiazem + Atenolol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study: 7025777

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 17
Study: 31081575

Group type: EXPERIMENTAL
Intervention: RCTs published from 2008 to 2017
Number of subjects: 96

Group type: COMPARATOR
Intervention: RCTs published from 1988 to 1997
Number of subjects: 96
Study: 28257920

Group type: EXPERIMENTAL
Intervention: Personalized web‐based counseling and decision support tool
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Standard educational content
Number of subjects: 1250
Study: 26081471

Group type: EXPERIMENTAL
Intervention: γ‐loop
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: υ‐loop
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 38
Study: 23789564

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 0
Study: 21694614

Group type: EXPERIMENTAL
Intervention: Mifepristone (300, 600, or 1200 mg)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Mifepristone (plasma concentrations > 1660 ng/mL)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study: 18094272

Group type: EXPERIMENTAL
Intervention: iodixanol 320
Number of subjects: 72

Group type: COMPARATOR
Intervention: iohexol 350
Number of subjects: 72
Study: 16418022

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered before surgery (PRE group)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered after surgery (POST group)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No intervention (CONT group)
Number of subjects: 111
Study: 12628531

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 36
Study: 10693082

Group type: EXPERIMENTAL
Intervention: Newborns from Las Vegas (exposed to perchlorate)
Number of subjects: 23000

Group type: COMPARATOR
Intervention: Newborns from Reno (not exposed to perchlorate)
Number of subjects: 23000

Group type: EXPERIMENTAL
Intervention: Temporal differences in mean T4 levels in both cities
Number of subjects: 23000

Group type: EXPERIMENTAL
Intervention: Effects of gender, birth weight, and day of life
Number of subjects: 23000

Group type: EXPERIMENTAL
Intervention: Environmental exposures to perchlorate (up to 15 micrograms/L)
Number of subjects: 23000
Study: 9465587

Group type: EXPERIMENTAL
Intervention: EBRT combined with BRTX (mean dose 50.2 +/- 13.2 Gy, dose rate of 0.3-0.4 Gy/hr)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard EBRT (mean dose 51.5 +/- 12.4 Gy in 2.0 Gy fractions)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: EBRT combined with BRTX for glioblastoma multiforme
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: BRTX as an adjuvant to EBRT
Number of subjects: 83
Study: 7682427

Group type: EXPERIMENTAL
Intervention: Epirubicin, methotrexate and bleomycin (EMB)
Number of subjects: 53

Group type: COMPARATOR
Intervention: cisplatin-methotrexate-bleomycin (DMB)
Number of subjects: 53
Study: 3332129

Group type: EXPERIMENTAL
Intervention: 10 Gy single dose TBI (n = 27)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 9.2 Gy single dose TBI (n = 22)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 6 x 2 Gy fractionated TBI (n = 26)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 9.2 Gy single dose TBI
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 9.2 Gy single dose TBI and 10 Gy single dose TBI
Number of subjects: 75

Group type: COMPARATOR
Intervention: 6 x 2 Gy fractionated TBI
Number of subjects: 75
Study: 29069383

Group type: COMPARATOR
Intervention: Tooth-borne (TB) rapid maxillary expansion (RME)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tooth-bone-borne (TBB) rapid maxillary expansion (RME)
Number of subjects: 40
Study: 27096580

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min, cycle ergometer, 50% of peak oxygen uptake)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest (seated, 45 min)
Number of subjects: 9
Study: 24767551

Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste (metronidazole, ciprofloxacin, and minocycline) (TAP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of calcium hydroxide and 2% chlorhexidine gel (CHP)
Number of subjects: 23
Study: 23297563

Group type: EXPERIMENTAL
Intervention: Moxibustion over Zusanli (ST 36) for 20 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxibustion over Hegu (LI 4) for 20 min
Number of subjects: 30
Study: 20056686

Group type: COMPARATOR
Intervention: Kaletra tablets (400 mg of lopinavir)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lopimune granules (400 mg of lopinavir)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lopimune paediatric tablets (400 mg of lopinavir)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lopimune granules with food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Kaletra solution with food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lopimune formulations
Number of subjects: 12
Study: 18228124

Group type: EXPERIMENTAL
Intervention: CDC language on condom effectiveness
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Proposed FDA label
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Current label on condom packaging
Number of subjects: 1194
Study: 15630410

Group type: EXPERIMENTAL
Intervention: val66met SNP (allele G) in schizophrenia group
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: haplotype analysis of val/met SNP and dinucleotide repeat polymorphism
Number of subjects: 584

Group type: COMPARATOR
Intervention: Control group (350 individuals)
Number of subjects: 584
Study: 14738367

Group type: EXPERIMENTAL
Intervention: Video of appropriate throwing mechanics
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Text information describing appropriate mechanics of the overhand throw
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination of video and text information
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 10370680

Group type: EXPERIMENTAL
Intervention: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in intermediate viral load group
Number of subjects: 154

Group type: COMPARATOR
Intervention: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in intermediate viral load group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in genotype 2 patients
Number of subjects: 154

Group type: COMPARATOR
Intervention: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in genotype 2 patients
Number of subjects: 154
Study: 8900905

Group type: EXPERIMENTAL
Intervention: Cholic acid (500 mg/day for 4 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (500 mg/day for 4 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Deoxycholic acid (500 mg/day for 4 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Paromomycin (1 g/day for 2 weeks)
Number of subjects: 23
Study: 1807272

Group type: EXPERIMENTAL
Intervention: Inhaled toxic chemicals (phenol <0.0025 ppm, ethyl alcohol <0.5 ppm, formaldehyde <0.2 ppm, chlorine <0.3 ppm, pesticide 2,3-D <0.0034 ppm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebos (water or saline)
Number of subjects: 50
Study: 6637574

Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 42

Group type: COMPARATOR
Intervention: metrizoate (Isopaque)
Number of subjects: 42
Study: 31146326

Group type: EXPERIMENTAL
Intervention: Dehydration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 12
Study: 29278526

Group type: EXPERIMENTAL
Intervention: Flipped learning
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional learning
Number of subjects: 108
Study: 26211687

Group type: EXPERIMENTAL
Intervention: ProArgin(™) paste
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gluma(®) Desensitizer
Number of subjects: 56

Group type: COMPARATOR
Intervention: NovaMin(®) paste
Number of subjects: 56
Study: 24963110

Group type: EXPERIMENTAL
Intervention: Automated closed-loop insulin delivery
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump therapy (SAP)
Number of subjects: 17
Study: 22554052

Group type: EXPERIMENTAL
Intervention: Active video game intervention (PlayStation EyeToy™)
Number of subjects: 322
Study: 19528843

Group type: EXPERIMENTAL
Intervention: Nonlinear periodized (NLP) resistance training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Linear periodized (LP) resistance training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nonperiodized (NP) resistance training
Number of subjects: 27
Study: 17487114

Group type: EXPERIMENTAL
Intervention: Ultrasound gel
Number of subjects: 346

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 346
Study: 15600245

Group type: EXPERIMENTAL
Intervention: TMC-114
Number of subjects: 0
Study: 11443021

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 332

Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 332
Study: 9498972

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (Azmacort) oral inhaler 4 puffs twice daily (800 microg daily) for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IV hydrocortisone (3 microg/kg/min) as a 14-h continuous infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7702445

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/d
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/d
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/d
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 2565723

Group type: EXPERIMENTAL
Intervention: Knee-chest position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall emesis episodes
Number of subjects: 20
Study: 970609

Group type: EXPERIMENTAL
Intervention: 1-0% etidocaine with 1/200,000 adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-5% lignocaine with 1/200,000 adrenaline
Number of subjects: 0
Study: 31522376

Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling for HPV
Number of subjects: 43
Study: 31017076

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention (n = 89)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual-care control group (n = 84)
Number of subjects: 173
Study: 29192798

Group type: EXPERIMENTAL
Intervention: Nutrition education and fruit and vegetable (F/V) supplementation
Number of subjects: 0
Study: 26991958

Group type: EXPERIMENTAL
Intervention: Double-dorsal injection
Number of subjects: 86

Group type: COMPARATOR
Intervention: Single-volar injection
Number of subjects: 86
Study: 25547580

Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 10° group (15 eyes)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 20° group (17 eyes)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 30° group (17 eyes)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 40° group (16 eyes)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison of intubation success rates
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Successful intubation cases
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Angle θ of successful intubation cases
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CT scan after successful intubation
Number of subjects: 54
Study: 22863660

Group type: EXPERIMENTAL
Intervention: CYD-TDV (3 injections at months 0, 6, and 12)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo (2 injections at months 0 and 6) or pneumococcal polysaccharide vaccine (month 12)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (placebo or pneumococcal polysaccharide vaccine)
Number of subjects: 298
Study: 20060105

Group type: EXPERIMENTAL
Intervention: Real high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC
Number of subjects: 38
Study: 18775200

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/d) with extended-release oxybutynin (10 mg/d)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg/d) alone (Control)
Number of subjects: 420
Study: 15969702

Group type: EXPERIMENTAL
Intervention: Recruitment strategy involving a screening survey and informational meetings with RO representatives.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eligible ROs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Size of the RO and the number of years that the religious leader had been with the RO.
Number of subjects: 100
Study: 11268029

Group type: EXPERIMENTAL
Intervention: Index of polyneuropathy (IPN)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neuropathy symptom score (NSS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neuropathy disability score (NDS)
Number of subjects: 38
Study: 9626637

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8534380

Group type: EXPERIMENTAL
Intervention: Potassium nitrate/copolymer/pyrophosphate dentifrice
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 67
Study: 2896581

Group type: EXPERIMENTAL
Intervention: HRP112 (depot‐medroxyprogesterone acetate, 25mg and estradiol cypionate, 5 mg)
Number of subjects: 2328

Group type: COMPARATOR
Intervention: HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg)
Number of subjects: 2328

Group type: EXPERIMENTAL
Intervention: HRP112
Number of subjects: 2328

Group type: COMPARATOR
Intervention: HRP102
Number of subjects: 2328